NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
* Return to Angiogenesis Alert Section

Data on angiogenesis published by researchers at University Hospital, Department of Medicine



March 9th, 2009

   2009 MAR 9 -- Data detailed in 'Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation' have been presented. According to recent research published in the Journal of Vascular Research, "We have previously demonstrated that iloprost, a stable prostacyclin (PGI(2)) analogue, induces angiogenesis in vivo, through a vascular endothelial growth factor (VEGF)-dependent mechanism. In this study, we demonstrate that iloprost-induced angiogenesis and VEGF upregulation are modulated by peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-inducible transcription factor that belongs to the nuclear hormone receptor superfamily and plays multiple biological activities in the vascular system."

   "We show that iloprost is unable to induce angiogenesis in mice lacking the PPARalpha gene (PPARalpha-/-mice). Likewise, iloprost-induced VEGF upregulation is absent in PPARalpha-/-mice. In contrast, iloprost induces a robust angiogenic response in wild-type mice, along with local upregulation of VEGF. Importantly, mice lacking the PPARalpha gene exhibit a normal angiogenic response to VEGF, indicating that the absence of PPARalpha does not result in a general impairment of angiogenesis, but specifically affects the ability of iloprost to induce angiogenesis," wrote F. Biscetti and colleagues, University Hospital, Department of Medicine.

   The researchers concluded: "Our data demonstrate unexpected functional relationships between the PGI(2) system and the PPAR signaling pathway and shed new light on the molecular mechanisms involved in iloprost-induced angiogenesis."

   Biscetti and colleagues published their study in the Journal of Vascular Research (Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. Journal of Vascular Research, 2009;46(2):103-8).

   For additional information, contact F. Biscetti, A Gemelli University Hospital, A Gemelli University Hospital, Dept. of Medicine, Rome, Italy.

   The publisher's contact information for the Journal of Vascular Research is: S. Karger AG, Allschwilerstrasse 10, CH-4009 Basel, Switzerland.

   Keywords: Italy, Rome, Angiogenesis, Drugs, Hormones, Iloprost, Oncology, Pharmaceuticals, Therapy, Treatment, Tumor Vascularization, VEGF, Vascular Endothelial Growth Factor.

   This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

Return to Angiogenesis Alert Section

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login